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Abstract The pharmacology and clinical application of tradi-
tional Chinese medicine has been extensively documented. We
have used an in vitro model system, PC12 cells, to demonstrate
the presence of neuroactive compounds in Ganoderma lucidum
(lingzhi). Ganoderma extract induced the neuronal differentia-
tion of PC12 cells and prevented nerve growth factor-dependent
PC12 neurons from apoptosis. Moreover, these effects of
ganoderma might be mediated via the ras/extracellular signal-
regulated kinase (Erk) and cAMP-response element binding
protein (CREB) signaling pathways, as demonstrated by the
phosphorylation of Erk1, Erk2 and CREB. Thus, our data not
only present the first evidence of the presence of neuroactive
compounds that mediate the neuronal differentiation and
neuroprotection of the PC12 cells, but also reveal the potential
signaling molecules involved in its action. ß 2000 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
The pharmacology and clinical application of traditional
Chinese medicine (TCM) has been well-documented for cen-
turies in China. The most ancient TCM herbals ‘Shen Nong
Ben Cao Jin’, which was compiled in around 100 A.D., clas-
si¢ed 365 herbs into three di¡erent categories. One important
category comprises novel Chinese herbs that are e¡ective in
promoting good health and vitality, and in curing various
diseases. Ganoderma lucidum (ganoderma or lingzhi), a medic-
inal Chinese mushroom belonging to this novel category, has
been demonstrated to possess tumoricidal [1,2] as well as im-
munomodulatory activities [3,4]. From the ethnopharmaco-
logical point of view, ganoderma is as important as ginseng
in China. Although the bene¢ts of ganoderma to brain and its
action in the suppression of in£ammation have been noted in
Chinese herbals, little is known regarding its actions and the
underlying mechanisms in brain. On the contrary, increasing
evidence has been accumulated on the medicinal application
of ganoderma in the treatment of various diseases, such as
cancers, immunological disorders and scleroderma [5,6].
The high nutritional value, wide acceptability, and potential
medicinal value of ganoderma, have attracted intense interest
in the search for pharmacological compounds from these edi-
ble mushrooms [5]. As a ¢rst step to examine potential neural
action(s) of ganoderma, we employed an in vitro model sys-
tem to examine the presence of neuroactive substances in ga-
noderma. Rat pheochromocytoma cell cultures, PC12 cells,
have been extensively used as model systems for the study
of tumorigenesis, apoptosis and neurodegenerative diseases
[7^9]. These cells di¡erentiate into dopaminergic neurons
when treated with nerve growth factor (NGF) even at very
low concentrations [10].
In this study, we report that ganoderma extract can reduce
the cell proliferation rate of PC12 cells. Furthermore, gano-
derma extract can also induce the neuronal di¡erentiation of
PC12 cells and prevent the NGF-dependent PC12 neurons
from undergoing apoptosis. More importantly, our ¢ndings
demonstrate that ganoderma extract can activate both the
MAP kinase and cAMP-response element binding protein
(CREB) signaling pathways, thus revealing the potential sig-
naling molecules involved in its action.
2. Materials and methods
2.1. Preparation of mushroom extracts
Ganoderma was cultivated as suspension cultures in 10 ml of po-
tato dextrose broth (Oxoid) at 25‡C until complete saturation. Typi-
cally, 600^700 mg of fungal mycelia was obtained. Fungal mycelia,
collected by ¢ltration, were washed and resuspended in deionized
water. Aqueous extract was obtained by autoclaving the ganoderma
suspension for 20 min.
2.2. Quantitative analysis of polysaccharides in ganoderma extracts
Quantitative analysis of the polysaccharides present in the ganoder-
ma extracts was performed by the phenol^sulfuric acid assay [11]. 1 ml
of ganoderma extract was mixed with 1.6 ml 5% phenol and 7.5 ml
concentrated H2SO4. After an incubation of 26 min, the solution was
degassed and measured at 497 nm (Spectronic Genesys 5). Glucose
standard solution was used as standard in the quantitative analysis.
2.3. Cell culture
Rat PC12 cells were cultured as previously described [7]. PC12 cells
were maintained in Dulbecco’s modi¢ed Eagle’s medium (DMEM;
high glucose formulation) supplemented with 6% fetal bovine serum
(FBS, Gibco) and 6% horse serum (HS, Gibco). As control, PC12
cells were di¡erentiated using NGF (10 ng/ml) (Alomone Lab).
2.4. Western blot analysis and antibodies
Protein extraction and Western blot analysis were performed as
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previously described [12]. Immunoreactive bands were detected using
an enhanced chemiluminescence kit (Amersham) and visualized by
Fuji X-ray ¢lm (Fuji). Monoclonal antibodies detecting the prolifer-
ating cell nuclear antigen (PCNA) and L-actin, and panTrk antibodies
for immunoprecipitation were obtained from Santa Cruz. Monoclonal
mouse anti-sera speci¢c for neuro¢lament-160 kDa phosphorylated
(Zymed), and neuro¢lament-200 kDa (Zymed) were used as neuronal
markers in the study. Rabbit polyclonal anti-sera detecting the phos-
phorylated and unphosphorylated forms of transcription factor
CREB, p44/42 MAP kinases (extracellular signal-regulated kinases;
Erk1/2), and the high a⁄nity NGF receptor, TrkA, were obtained
from New England Biolabs. Quantitation was performed using the
integrated density and concentration analysis provided by the Eagle-
Sight software (Stratagene).
2.5. Cell proliferation and viability of PC12 cells
The e¡ect of ganoderma extract on cell proliferation and viability
was monitored by measuring the reduction of the tetrazolium salt
using the cell proliferation (MTT) kit (Roche Molecular Biochemi-
cals). Brie£y, PC12 cells (1000 cells/well) were preincubated overnight
in 96-well plates. The cells were then treated with ganoderma extract
at di¡erent concentrations (5^100 mg/ml) for 2 or 4 days. MTT assays
were performed by incubating the ganoderma treated PC12 cells with
MTT labeling solution. After 4 h of incubation, PC12 cells were lyzed
and the purple formazan crystals were solubilized for detection at 570
nm. At least three independent experiments were performed for each
study; representative data is presented.
2.6. Cytotoxicity assays
The cytotoxic potential of the ganoderma extract was determined
by the cytotoxicity detection kit (Roche Molecular Biochemicals)
which was based on the detection of lactate dehydrogenase (LDH)
released from dead cells as a result of cytotoxicity. Cell-free culture
supernatants from ganoderma treated PC12 cells were collected and
then transferred to multi-titer plates. Substrate mixture containing
tetrazolium salts were added, and then incubated for 0.5 h. The for-
mazan dye formed was quantitated by measuring the absorbance at
500 nm.
2.7. Anti-apoptotic e¡ects of ganoderma extract
Apoptosis of PC12 cells induced by NGF withdrawal was per-
formed as described with minor modi¢cations [13]. Brie£y, PC12 cells
were treated with NGF (50 ng/ml) for at least 7 days in 0.1% HS/FBS
on collagen-coated plates. Apoptosis was induced by washing the
NGF-induced PC12 neurons twice with serum-free DMEM, followed
by treatment with ganoderma extracts (50 mg/ml in DMEM). In the
control setup, an equal amount of water or 50 ng/ml NGF was added.
PC12 neurons were then cultured for 12 h before they were air-dried
and ¢xed in 4% paraformaldehyde (Fluka). Detection of apoptotic cell
death was performed using the £uorescein-based in situ cell death
detection kit (Roche Molecular Biochemicals). The assay was based
upon the detection of DNA degradation using TUNEL staining. Ap-
optotic cells were visualized under a Zeiss Axioplot £uorescence
microscope (Zeiss). The extent of apoptosis was expressed as a per-
centage of the total number of cells that showed positive TUNEL
staining. Typically, at least 300 cells per treatment were counted in
random ¢elds. At least three independent experiments were performed
for each study; representative data is presented.
3. Results
3.1. Ganoderma extract inhibited the proliferation of rat PC12
cells with no detectable cytotoxicity
As the ¢rst step to examine the presence of neuroactive
compounds in ganoderma, we utilized an in vitro model sys-
tem using rat PC12 cells. When challenged with low concen-
trations of NGF (6 10 ng/ml), PC12 cells undergo neuronal
di¡erentiation with extensive neurite outgrowth and expres-
sion of neuronal proteins such as neuro¢laments. Aqueous
extracts of ganoderma, containing 16.5 Wg/Wl of polysacchar-
ides (40.6% (w/w)), were added to the PC12 cells cultured in
normal medium. The e¡ect on the cell proliferation was ex-
amined by monitoring the metabolic activities of PC12 cells
after treatment with increasing concentrations of ganoderma
extract for 2 or 4 days.
At day 2, treatment of PC12 cells with ganoderma extract
at high concentrations (s 50 mg/ml) signi¢cantly decreased
the growth rate when compared with the control cells treated
with the solvent, i.e. water (Fig. 1). At day 4, ganoderma
extracts signi¢cantly reduced the cell proliferation of PC12
cells in a dose-dependent manner. More than 30% decrease
in cell proliferation was observed when PC12 cells were
treated with 100 mg/ml ganoderma extract for 4 days.
Since the cell proliferation MTT assays measure the meta-
bolic activities of the cells, the reduction in the absorbance
could either be a consequence of cell death or the reduction inTable 1
Cytotoxic e¡ect of ganoderma extract on PC12 cells
Treatment Average absorbance
Ganoderma (mg/ml)
0 0.704 þ 0.01
5 0.776 þ 0.01
10 0.791 þ 0.01
25 0.794 þ 0.01
50 0.767 þ 0.02
100 0.812 þ 0.02
Control
Total cell lysate 2.175 þ 0.09
NGF (12.5 ng/ml) 0.774 þ 0.01
The cytotoxic e¡ect of ganoderma extract was determined by mea-
suring the LDH released from the cytosol of dead cells. PC12 cells
were treated with ganoderma extract at working concentration as
indicated for 24 h. As control, PC12 cells were treated with NGF
which was capable of di¡erentiating PC12 cells into sympathetic
neurons. Cell-free supernatant was collected and the LDH released
by dead cells was quantitated by adding substrate mixture contain-
ing p-iodonitrotetrazolium violet and sodium lactate. Water-soluble
formazan dye was detected directly at 490 nm. Total cell lysate, in-
dicating the maximum releasable LDH in PC12 cells, was prepared
by incubating the PC12 cells with 2% Triton X-100 in assay me-
dium. Experiments were performed at least three times and results
indicated in the table were mean þ S.E.M. in one representative ex-
periment; n = 5. Ganoderma extract alone did not give positive ab-
sorbance (data not shown).
Fig. 1. E¡ect of ganoderma extract on the cell proliferation of
PC12 cells. PC12 cells were treated with aqueous ganoderma extract
at concentrations from 5 to 100 mg/ml for 2 or 4 days. NGF
(12.5 ng/ml) was used as a positive control in the experiment. MTT
assays were performed as described. The mean absorbance obtained
using solvent control was designated 100%. Results shown represent
the mean þ S.E.M. of a typical experiment; n = 3.
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the cell proliferation. The cytotoxicity test was then performed
to examine whether treatment of PC12 cells with the ganoder-
ma extract could induce cell death. Increasing concentrations
of ganoderma extract (5 to 100 mg/ml) was added to PC12
cells and the release of LDH was monitored after overnight
incubation. It was observed that the ganoderma extracts did
not induce any detectable cytotoxic e¡ect (Table 1).
3.2. Ganoderma extracts induced the neuronal di¡erentiation
of PC12 cells
Following treatment with ganoderma extract, PC12 cells
showed neuronal phenotypes, including compaction of cell
bodies and the extension of neurites (Fig. 2). Although not
all PC12 cells di¡erentiated into neuron-like cells even at day
14 of the ganoderma treatment, the ¢rst occurrence of neu-
ron-like cells was comparable to that observed with NGF
treatment. Total proteins were prepared from PC12 cells
treated with ganoderma extract for 3 to 14 days as well as
from PC12 cells treated with NGF (10 ng/ml). Immunoblot-
ting was performed to examine the expression of neuronal
markers in the PC12 cells treated with ganoderma extract. It
was observed that the ganoderma extracts induced the expres-
sion of neuronal markers including phosphorylated forms of
the 200 kDa neuro¢lament (NF-H-P), and 160 kDa neuro¢la-
ment (NF-M-P) (Fig. 3). Since the neuro¢laments are the
major proteins of the neuronal cytoskeleton, our ¢ndings sug-
gested that the ganoderma extract contained neuroactive com-
pounds that induced the neuronal di¡erentiation of PC12
cells.
3.3. Ganoderma extract rescued the PC12 neurons from
apoptosis induced by NGF withdrawal
Following NGF treatment, PC12 cells di¡erentiate into
neurons which will undergo apoptosis upon NGF withdrawal
Fig. 2. Morphology of PC12 cells treated with ganoderma extracts. PC12 cells were treated with ganoderma extract (50 mg/ml) for the period
indicated. PC12 cells treated with either solvent alone or NGF (10 ng/ml) were used as negative and positive control, respectively.
Fig. 3. Expression of neuro¢lament proteins following treatment of
PC12 cells with ganoderma extract. PC12 cells were treated with
aqueous ganoderma extract at concentrations of 50 mg/ml for 3 to
14 days. NGF (10 ng/ml) was used as the positive control. Total
proteins were prepared and Western blot analysis was performed us-
ing antibodies speci¢c for NF-H-P, NF-M-P and actin as indicated
on the right. Positions of the protein size markers are as indicated.
FEBS 24409 11-12-00
W.M.W. Cheung et al./FEBS Letters 486 (2000) 291^296 293
[14]. The ability of the ganoderma extract to protect these
neurons from undergoing apoptosis was examined. NGF-de-
pendent neurons were prepared by di¡erentiating the PC12
cells in 50 ng/ml NGF for 8 days, and apoptosis was induced
by the removal of NGF for 12 h. During the NGF withdrawal
Fig. 5. Ganoderma extract activated the MAP kinases and CREB but not the TrkA proteins. PC12 cells were serum-starved for 5 h, and then
treated with aqueous ganoderma extract (50 and 100 mg/ml) for various times as indicated. NGF (10 ng/ml) was used as the positive control.
A: Total cell lysate was immunoprecipitated with panTrk antibodies in total alkaline RIPA at 4‡C. Precipitated proteins were subjected to
SDS^PAGE, electrotransferred to nitrocellulose and immunoblotted with phospho-TrkA (pTrkA) antibodies. The membrane was subsequently
stripped and reblotted with anti-TrkA antibodies as indicated. Total lysates were immunoblotted with PCNA to demonstrate equal quantities
of protein employed for the immunoprecipitation. B: Total lysates were immunoblotted with antibodies speci¢c for the phosphorylated proteins
(pErk1/2 and pCREB), or the phosphorylation-independent state of the corresponding proteins (TrkA, Erk1/2 and CREB), as indicated on the
right. Positions of the protein size markers are as indicated. C: Quantitative analysis of pErk1/2 and Erk1/2 expression was performed as de-
scribed in Section 2. The quantitative data were normalized relative to control and expressed as fold stimulation. Results from three separate
experiments are expressed as mean þ S.E.M. *P6 0.001 and **P6 0.01, unpaired t-test, compared with control.
Fig. 4. Ganoderma extract protected PC12 neurons from NGF
withdrawal apoptosis. PC12 cells were cultured in normal medium
supplemented with 50 ng/ml for 8 days. After two washes with
NGF-free normal medium, the neurons were cultured in normal me-
dium supplemented with water, 50 mg/ml ganoderma extract, or
50 ng/ml NGF for 12 h. TUNEL staining was performed as de-
scribed. Apoptotic cells with positive £uorescent staining were
scored and expressed as the percentage of total number of cells. Re-
sults shown are the mean þ S.E.M. of a typical experiment; n = 3.
6
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period, PC12 cells were either treated with ganoderma extract
(50 mg/ml) or NGF (50 ng/ml). TUNEL staining was per-
formed to detect the apoptotic cells and the TUNEL stained
PC12 cells were scored. While NGF withdrawal induced 60%
of the PC12 neurons to undergo apoptosis, treatment with
ganoderma extract (50 mg/ml) reduced the extent of apoptosis
to 15% (Fig. 4).
3.4. The MAP kinases, but not TrkA, were activated during the
neuronal di¡erentiation of PC12 cells induced by
ganoderma extracts
In order to examine whether the neuroactivity of ganoder-
ma was mediated by NGF-like activities, we investigated the
ability of ganoderma extract to activate TrkA. Total protein
was collected from PC12 cells that were treated with ganoder-
ma extracts for 15 min. Immunoblotting was performed using
speci¢c antibodies that detected the phosphorylated form of
TrkA. It was observed that the ganoderma extracts neither
activated any detectable phosphorylation of TrkA nor in-
creased the expression of TrkA protein (Fig. 5A). Thus, the
ability of ganoderma extract to induce neuronal di¡erentia-
tion of PC12 cells was mediated by a signaling pathway that
did not involve TrkA activation.
Phosphorylation assays were performed to examine the pos-
sible involvement of the ras/Erk pathway and the CREB path-
way. When PC12 cells were treated with ganoderma extract
(50 or 100 mg/ml), both Erk1 and Erk2 were activated (Fig.
5B, top panels) for at least 30 min. The quantitative analysis
from three independent experiments is depicted in Fig. 5C. In
addition to Erk activation, the ganoderma extract could also
activate CREB via the phosphorylation at the serine-133 (Fig.
5B, lower panels).
4. Discussion
In the present study, we utilized a model system, PC12 cells,
to demonstrate the presence of neuroactive compounds in the
Chinese mushroom, G. lucidum. Incubation with ganoderma
extract results in a reduction of cell proliferation, as well as
induction of neuronal di¡erentiation of PC12 cells. More im-
portantly, the ganoderma extract also protects the neurons
from apoptosis induced by NGF withdrawal. Furthermore,
the ability of ganoderma extract to induce the phosphoryla-
tion of both Erk1/2 and CREB proteins in PC12 cells suggests
that the action of ganoderma may be mediated via both the
ras/Erk and CREB signaling pathways. Our ¢ndings not only
demonstrate that G. lucidum comprises a rich source of neuro-
active compounds, but also reveals the potential signaling
molecules involved in its action.
The anti-tumor e¡ect of ganoderma has been suggested to
result from immunosuppressive protein [15,16], inhibition of
DNA polymerase by cerebrosides [17] or inhibition of post-
translational modi¢cation of oncoproteins [18]. Polysaccha-
rides containing anti-tumor activities, with molecular weights
ranging from 4U105 to 1U106, have also been extracted from
several species of ganoderma [2,19]. Recent ¢ndings suggest
that the anti-tumor e¡ect of ganoderma mediated by the pol-
ysaccharides is a consequence of the potentiation of cytokine
production by activated macrophages and T lymphocytes
[20,21]. In light of the high percentage (40% (w/w)) of poly-
saccharides present in our ganoderma extract, polysaccharides
are likely candidates for mediation of the neuroactivity ob-
served in this study. During the mycelial growth, the polysac-
charides can be secreted to the culture media [22]. This is
consistent with our recent ¢ndings that the ganoderma culture
¢ltrate can reduce the cell proliferation of PC12 cells to the
same extent as the autoclaved aqueous extract. Furthermore,
similar Erks activation can also be demonstrated using a com-
mercially available preparation of ganoderma that is enriched
in polysaccharides (data not shown). Work is in progress in
our laboratory to determine the precise identity of the neuro-
active compounds in the ganoderma extract.
Since very little is known regarding the molecular mecha-
nism underlying the action of ganoderma, our ¢ndings present
the ¢rst evidence on the potential signaling molecules in-
volved, such as the ras/Erk signaling pathway. This pathway
involves protein kinases that are important in regulating the
growth and di¡erentiation of PC12 cells [23]. Although gano-
derma extract does not directly activate TrkA, its action may
be mediated by other types of receptors, the stimulation of
which leads to activation of the downstream ras/Erk signaling
cascade. It has been reported that NGF deprivation inhibits
the phosphorylation of the Erks but activated the c-Jun NH2-
terminal protein kinase and p38 kinase [24]. Thus, the neuro-
protective e¡ect of the ganoderma extract may be explained
by the activation of Erks that maintain the survival of the
NGF-dependent neurons. Furthermore, our ¢nding on the
activation of CREB upon treatment with ganoderma raises
the intriguing possibility that ganoderma may mediate neuro-
nal functions by modulating the activities of di¡erent signal-
ing pathways. For example, recent studies demonstrate the
importance of CREB signaling on learning and memory [25]
and hyperphosphorylation of CREB plays an important role
in the long-term potentiation of the hippocampus [26]. It will
be of interest to examine the potential use of ganoderma ex-
tract in the enhancement of memory.
The involvement of abnormal apoptosis, which results in
excessive loss of neurons, has been demonstrated in various
neurodegenerative diseases [27]. We report here that the ga-
noderma extract contains neuroactive compounds which can
prevent cell death in NGF deprived PC12 neurons. Taken
together with the data on the low cytotoxicity and high nu-
tritive value of ganoderma, our ¢nding reveals the potential
use of ganoderma extract in protecting the neurons from
undergoing apoptosis, such as that in disease states. Although
pharmacological agents such as calpain and caspase inhibitors
possess remarkable neuroprotective e¡ects, they show distinc-
tive modes of action [28]. It will be of interest to examine
whether the ganoderma extract can have additive or synergis-
tic e¡ects with these agents in the prevention of neuronal ap-
optosis.
While the present study reports the ¢rst evidence on the
neuroactive actions of ganoderma polysaccharides, the bioac-
tive compounds that are responsible for the neuroactivity re-
main to be determined. It is noteworthy that a common and
interesting feature of TCM is the presence of multiple com-
pounds which could act either independently or synergistically
to elicit their pharmacological e¡ects. Our assay systems pre-
sented in this report may serve as a good bioassay system for
such systematic analysis.
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